RRC ID 66107
Author Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y, Kondo E, Sone M, Yasoda A, Inagaki N.
Title Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Journal Thyroid
Abstract BACKGROUND:The programmed cell death-1 (PD-1) pathway is a novel therapeutic target in immune checkpoint therapy for cancer. It consists of the PD-1 receptor and its two ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Nivolumab is an anti-PD-1 monoclonal antibody approved for malignant melanoma, advanced non-small cell lung cancer, and advanced renal cell carcinoma in Japan. Thyrotoxicosis and hypothyroidism have both been reported in international Phase 3 studies and national post-marketing surveillance of nivolumab in Japan.
METHODS:This study analyzed five consecutive cases with thyroid dysfunction associated with nivolumab therapy. Second, it examined the mRNA and protein expressions of PD-L1 and PD-L2 by reverse transcription polymerase chain reaction and Western blotting.
RESULTS:All patients were diagnosed with painless thyroiditis. Thyrotoxicosis developed within four weeks from the first administration of nivolumab and normalized within four weeks of onset in three of the five patients. Hypothyroidism after transient thyrotoxicosis developed in two patients, and preexisting hypothyroidism persisted in one patient. The other two patients were treated with glucocorticoids and discontinued nivolumab therapy for comorbid adverse events. One did not develop hypothyroidism, and the other developed mild, transient hypothyroidism. In addition, it was verified that normal thyroid tissue expresses PD-L1 and PD-L2 mRNA and those proteins.
CONCLUSIONS:In the present cases, nivolumab-induced thyrotoxicosis seemed to be associated with painless thyroiditis, while no patient with Graves' disease was observed. A transient and rapid course with subsequent hypothyroidism was observed in nivolumab-induced thyroiditis. In addition, it was verified that PD-L1 and PD-L2 are expressed in normal thyroid tissue. This suggests that nivolumab therapy reduces immune tolerance, even in normal thyroid tissue, and leads to the development of thyroiditis. Treating thyrotoxicosis with only supportive care and considering levothyroxine replacement therapy once subsequent hypothyroidism occurs is proposed. Further investigations are required to confirm whether glucocorticoid therapy and discontinuation of nivolumab therapy prevent subsequent hypothyroidism.
Volume 27(7)
Pages 894-901
Published 2017-7-1
DOI 10.1089/thy.2016.0562
PMID 28537531
MeSH Aged Antibodies, Monoclonal / adverse effects* Antineoplastic Agents / adverse effects* Breast Neoplasms / drug therapy Female Humans Lung Neoplasms / drug therapy Male Melanoma / drug therapy Middle Aged Nivolumab Skin Neoplasms / drug therapy Symptom Assessment Thyroiditis / blood Thyroiditis / chemically induced* Thyroiditis / diagnosis* Thyrotoxicosis / blood Thyrotoxicosis / chemically induced* Thyrotoxicosis / diagnosis* Thyrotropin / blood Thyroxine / blood Triiodothyronine / blood
IF 7.786
Resource
Human and Animal Cells MCF7(RCB1904) HeLa(RCB0007) HTC/C3(RCB0452)